Showing results 1 to 7 of 7
Title | Author(s) | Issue Date | Views | |
---|---|---|---|---|
2016 | 30 | |||
A phase I/II study of Foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC) Proceeding/Conference:Journal of Clinical Oncology | 2012 | 107 | ||
A Phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2 and VEGFR in advanced hepatocellular carcinoma (HCC) Proceeding/Conference:Journal of Hepatology | 2011 | 132 | ||
A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC) Proceeding/Conference:Journal of Clinical Oncology | 2012 | 102 | ||
2017 | 9 | |||
2015 | 48 | |||
2016 | 29 |